RxDoctor Payments Data

Margaret Matlock, APRN

Family · Chanute, KSNPI 1427680008

Payments from drug & device makers

$799in general payments, 2019–2025

Across 48 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$190
  • AbbVie$130
  • Bayer$81
  • Sanofi-aventis U.S. LLC$67
  • AstraZeneca$63
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61
  • plus $207 from 7 others

What the payments were for

  • Food & beverage$799100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$799 in reported general payments places this provider in the 65th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$3,641
Medicare patients
29
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$19,368
MyrbetriqMirabegron32$15,512
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,012
EliquisApixaban14$13,061
JanuviaSitagliptin Phosphate18$11,304
Breo ElliptaFluticasone/Vilanterol13$5,417
Incruse ElliptaUmeclidinium Bromide12$4,422
Dexlansoprazole DrDexlansoprazole17$2,573
PremarinEstrogens, Conjugated11$2,436
Olanzapine32$2,053
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,467
Potassium Chloride90$1,328
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$1,277
Duloxetine Hcl38$1,177
Rosuvastatin Calcium43$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$17$23,85145 claims
Novo NordiskOzempic$15$19,36820 claims
Lilly USA, LLCOlanzapine$27$2,05332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,579 family providers in Kansas.

Other family in Chanute

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →